Navigation Links
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:6/6/2011

SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).  Preliminary analysis demonstrates that the trial has met its primary endpoint.

FREEDOM-M was a randomized, double-blind, placebo-controlled trial of patients with PAH, a chronic, life-threatening illness.  The study enrolled 349 patients who were not receiving any approved PAH medication, with the population for the primary analysis consisting of the 228 patients who had access to the 0.25 mg tablet at randomization.  These patients were administered oral treprostinil or placebo twice daily, with the doses titrated to effect over the course of the 12-week trial.  The majority of patients were in World Health Organization (WHO) Functional Class II (~33%) and Class III (~66%) of varied etiologies, including idiopathic or familial PAH (~75%), collagen vascular disease associated PAH (~19%), and PAH associated with HIV or other associated conditions (~6%).  The patients’ mean baseline six-minute walk distance (6MWD) was approximately 330 meters.

The primary efficacy endpoint of the trial was the change in 6MWD at 12 weeks for the 228 patients.  Preliminary analysis of the FREEDOM-M results demonstrates that those patients receiving oral treprostinil improved their median 6MWD by approximately 23 meters (p=0.0125, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial’s pre-specified statistical analysis plan) as compared to patients receiving placebo.  The median change from baseline was 25 meters for oral treprost
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 The March 3, 2015, order from ... must change their products, labels to clarify the drugs, intended ... and stroke is necessary to protect the public from injury ... partner at Simmons Hanly Conroy . The ... that the products – currently taken by millions of U.S. ...
(Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
(Date:3/4/2015)... N.J. , March 4, 2015  Bayer ... Drug Administration (FDA) has accepted the company,s Biologics ... Factor VIII compound.  Bayer is seeking FDA approval ... for the treatment of hemophilia A in children ... to continually bringing new therapies to hemophilia A ...
Breaking Medicine Technology:Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
... , Fla., May 10 Dr. Richard ... with newly diagnosed type 1 diabetes for Protege Encore, a ... of two Phase III studies testing the safety and efficacy ... as Protege, has completed enrollment of more than 530 subjects ...
Cached Medicine Technology:Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:3/5/2015)... Obesity can cause the human body to ... drinks each day can help promote weight loss in ... advocate Sharon Kleyne and sports doctor Robert Weil, during ... of Water® radio show. , Weil is a ... and sports medicine. His weekly radio show, "The ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Hope For The ... Sporting Clay Shoot to be held at Beretta Shooting Grounds ... 2015. All proceeds from the event will benefit Hope For ... of self, restoring the family unit, and restoring hope for ... will honor our nation’s heroes through a day of clay ...
(Date:3/5/2015)... LOUISIANA (PRWEB) March 05, 2015 ... its continued support of the annual American Heart Association’s ... year, Bret Kolman, Lakeview Regional Chief Executive Officer, is ... place on Saturday, March 21, 2015 at Fontainebleau State ... sponsorship, Lakeview Regional has 20 individual teams participating in ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... Professor of Psychiatry and Psychology Department of Neuroscience, ... at the upcoming BioConference Live Neuroscience, a two-day ... , The webcast , titled “Dopamine System ... is scheduled for Thursday, March 18, from 9 ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... of the groundbreaking for Cielo Carmel on March 4 ... court will feature speakers: Sherri Lightner, Council president, ... Affirmed Housing; Charmaine Atherton, Senior Vice President, Southern ... Richard Gentry, President & CEO, San Diego Housing Commission. ...
Breaking Medicine News(10 mins):Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 2Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 3Health News:Hope For The Warriors Announces New York Clay Shoot to Benefit Military Families 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 3Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 2Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 3Health News:SD City Council President Sherri Lightner and Affirmed Housing Break Ground on Affordable Homes in Carmel Valley 2
... CLARA, Calif., Dec. 3 Coherent, Inc.,(Nasdaq: COHR ... received the,decision of the Board of Directors of The ... 2007 to file its past due periodic reports,for the ... quarterly periods,of 2007 with the Securities Exchange Commission ("SEC") ...
... Mass., Dec. 3 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... the annual American Society of Hematology (ASH) meeting ... visiting the Investors section of the,Company,s website, ... The presentation will be delivered by Millennium ...
... first survey to specifically measure hospital pediatric preparedness, a ... researchers found few U.S. emergency rooms are properly equipped ... Charles Schmitz and Roger J. Lewis was reported in ... the American Academy of Pediatrics. The team of LA ...
... care and lack of transportation combine to limit access, CDC ... Almost 20 percent of Americans, or more than 40 million ... a new U.S. government report released Monday. , Access to ... United States, 2007 report from the Centers for Disease ...
... Vegas and Tucson Marathon Runners, PLEASANT GROVE, Utah, ... to prevent inflammation and pain, but at the same ... at,Appalachian State University and Vanderbilt University, published in,Medicine & ... exercise may be unhealthy in the long term. The ...
... Front Needs of Families with Deployed Service Members ... ... will present $15,000 to the Missouri National Guard -,Missouri Military Family Relief Fund, ... their families., Don Brown, market vice president for the central market area ...
Cached Medicine News:Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 2Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 3Health News:Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event 2Health News:LA BioMed researchers find few emergency rooms fully equipped for pediatric patients 2Health News:Almost 1 in 5 Americans Going Without Health Care 2Health News:Almost 1 in 5 Americans Going Without Health Care 3Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2
... enables highly sensitive time-resolved fluorescence detection ... fluorophores. These compounds are excited with ... fluorescence lifetimes (several hundred microseconds), large ... profiles at 620 nm. Therefore with ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
Medicine Products: